Grant: Engage Grants Program
University of Calgary
$25,000.00
Role of Immunoglobulin Light Chain Derived Peptides in Preventing Multiple Myeloma Associated Cast Nephropathy
FY 2015-16
Summary
Thrasos Therapeutics Inc. is collaborating with Prof. David Schriemer (University of Calgary) to understand
molecular mechanisms involving a treatment of renal failure in cancer patients with multiple myeloma. This
cancer generates high levels of antibody byproducts in the urine, which interact with normal urine protein and
cause blockages called cast nephropathies. The incidence of renal failure from cast nephropathies is high, and
significantly adds to the mortality rate associated with multiple myeloma. The phenomenon is so common in
multiple myeloma that detection of these blockages confirms the presence of the cancer. Treatments that
eradicate or prevent the blockages are anticipated to improve patient health and improve overall survival rates.
Thrasos has an experimental therapy targeting the protein interaction, shown to reduce the formation of
blockages. However, the molecular properties behind the success of the experimental drug are unknown. We
seek to determine the nature of the molecular interactions that form the blockages, and how the drug interferes
with them. Protein structural analyses will be performed using mass spectrometric techniques, in order to map
the chemical nature and location of the binding domains between the antibody byproducts and the host protein.
These analyses will be extended to the drug/host-protein interaction, to identify the molecular features that
contribute to its success as a ""blockage-buster"".
Program
Engage Grants Program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
487164-2015
Name nom
Schriemer, David
Department département
Biochemistry and Molecular Biology
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Partie
1
Nb partie
1
Application title
Role of Immunoglobulin Light Chain Derived Peptides in Preventing Multiple Myeloma Associated Cast Nephropathy
Keyword
NSERC
Application summary
Thrasos Therapeutics Inc. is collaborating with Prof. David Schriemer (University of Calgary) to understand
molecular mechanisms involving a treatment of renal failure in cancer patients with multiple myeloma. This
cancer generates high levels of antibody byproducts in the urine, which interact with normal urine protein and
cause blockages called cast nephropathies. The incidence of renal failure from cast nephropathies is high, and
significantly adds to the mortality rate associated with multiple myeloma. The phenomenon is so common in
multiple myeloma that detection of these blockages confirms the presence of the cancer. Treatments that
eradicate or prevent the blockages are anticipated to improve patient health and improve overall survival rates.
Thrasos has an experimental therapy targeting the protein interaction, shown to reduce the formation of
blockages. However, the molecular properties behind the success of the experimental drug are unknown. We
seek to determine the nature of the molecular interactions that form the blockages, and how the drug interferes
with them. Protein structural analyses will be performed using mass spectrometric techniques, in order to map
the chemical nature and location of the binding domains between the antibody byproducts and the host protein.
These analyses will be extended to the drug/host-protein interaction, to identify the molecular features that
contribute to its success as a ""blockage-buster"".